SLNO Soleno Therapeutics, Inc. Stock Quote

SLNO [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-0.43	Insider Own	2.30%	Shs Outstand	79.73M	Perf Week	-4.84%
Market Cap	96.45M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	-0.13%	Shs Float	66.60M	Perf Month	-28.05%
Income	-24.60M	PEG	-	EPS next Q	-0.08	Inst Own	58.60%	Short Float	2.60%	Perf Quarter	-45.37%
Sales	-	P/S	-	EPS this Y	56.30%	Inst Trans	1.20%	Short Ratio	0.89	Perf Half Y	-40.10%
Book/sh	0.57	P/B	2.07	EPS next Y	6.50%	ROA	-39.80%	Target Price	-	Perf Year	-61.81%
Cash/sh	-	P/C	-	EPS next 5Y	15.00%	ROE	-61.90%	52W Range	1.11 - 4.39	Perf YTD	-38.86%
Dividend	-	P/FCF	-	EPS past 5Y	45.80%	ROI	-	52W High	-73.92%	Beta	0.44
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	-	Gross Margin	-	52W Low	3.14%	ATR	0.11
Employees	17	Current Ratio	5.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.68	Volatility	7.55% 7.60%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	89.90%	Profit Margin	-	Rel Volume	0.79	Prev Close	1.18
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.95M	Price	1.14
Recom	1.30	SMA20	-11.45%	SMA50	-42.22%	SMA200	-41.76%	Volume	381,916	Change	-2.97%

Sep-29-20

Initiated

Guggenheim

Buy

Jan-10-20

Initiated

Craig Hallum

Buy

Dec-23-19

Initiated

Oppenheimer

Outperform

$10

Feb-13-18

Reiterated

Maxim Group

Buy

$8 → $4

Apr-14-21 08:40PM	Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall GlobeNewswire
Mar-30-21 07:02AM	Soleno Therapeutics (SLNO) Enters Oversold Territory Zacks
Mar-29-21 10:05AM	Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation Simply Wall St.
Mar-09-21 04:01PM	Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference GlobeNewswire
11:00AM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the Firm ACCESSWIRE
06:40AM	Soleno Therapeutics (SLNO) Is in Oversold Territory: What's Next? Zacks
Mar-08-21 08:53AM	Soleno Shares Are Trading Lower After FDA Demands Additional Study For DCCR Program In Prader-Willi Syndrome Benzinga -48.70%
08:00AM	Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome GlobeNewswire
06:35AM	Soleno Slumps as FDA Requires Additional Trial for Drug TheStreet.com
Mar-03-21 04:01PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
Feb-23-21 09:38AM	Soleno Therapeutics, Vanderbilt University In Research Pact For K(ATP) Channel Activators Benzinga -7.29%
Feb-05-21 08:00AM	Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire
Jan-28-21 08:00AM	Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome GlobeNewswire
Jan-04-21 08:00AM	Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference GlobeNewswire
Dec-28-20 08:43AM	Have Insiders Been Buying Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares? Simply Wall St.
Dec-13-20 09:44PM	Is SLNO A Good Stock To Buy Now? Insider Monkey
Dec-11-20 08:30AM	Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome GlobeNewswire
Nov-10-20 04:01PM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-03-20 04:01PM	Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome GlobeNewswire
Oct-29-20 12:06PM	Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting GlobeNewswire
Oct-02-20 10:46AM	Soleno Therapeutics' Shares March Higher, Can It Continue? Zacks -7.42%
Sep-30-20 02:40PM	Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire +21.26%
Sep-15-20 08:00AM	Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire
Aug-20-20 08:35AM	Soleno (SLNO) in Focus: Stock Moves 6.3% Higher Zacks
Aug-10-20 04:01PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results GlobeNewswire +5.03%
Jul-27-20 10:09AM	Soleno (SLNO) to report Q2 Earnings: What's in the Cards? Zacks
Jun-29-20 09:07AM	Have Insiders Been Buying Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares? Simply Wall St. +13.04%
09:02AM	Trade Alert: Jack Schuler At Soleno Therapeutics, Inc. (NASDAQ:SLNO), Has Just Spent US$8.5m Buying 83% More Shares Simply Wall St.
08:00AM	Soleno Therapeutics Added to Russell 3000® Index GlobeNewswire
Jun-26-20 04:01PM	Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-20 11:15PM	Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher Zacks
04:03PM	Hedge Funds Have Never Been This Bullish On Soleno Therapeutics, Inc. (SLNO) Insider Monkey
Jun-24-20 08:31AM	Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock GlobeNewswire
Jun-23-20 04:01PM	Soleno Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-15-20 08:42AM	Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session Zacks
Jun-11-20 12:00PM	Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks -10.15%
Jun-09-20 07:46AM	The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates Benzinga -35.19%
06:12AM	Soleno Plunging 48% In Pre-Market On Obesity Study Failure SmarterAnalyst
Jun-08-20 04:01PM	Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire
09:49AM	3 Penny Stocks That Could Climb Over 140% TipRanks
Jun-01-20 08:37AM	Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options Zacks +8.33%
May-12-20 04:01PM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-23-20 08:00AM	Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity GlobeNewswire +8.70%
Mar-30-20 09:41AM	Here's Why We're Watching Soleno Therapeutics's (NASDAQ:SLNO) Cash Burn Situation Simply Wall St.
Mar-11-20 08:00AM	Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference GlobeNewswire -8.76%
Mar-04-20 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire +15.49%
Jan-20-20 04:37AM	3 Top-Notch Strong Buy Stocks Under $3 TipRanks
Jan-07-20 10:21AM	Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study Zacks
Jan-06-20 08:00AM	Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome GlobeNewswire +6.96%
Dec-23-19 07:52PM	Do Hedge Funds Love Soleno Therapeutics, Inc. (SLNO)? Insider Monkey +25.43%
Nov-13-19 08:00AM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results GlobeNewswire +10.00%
Oct-25-19 04:30PM	Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock GlobeNewswire
Oct-23-19 09:00AM	Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock GlobeNewswire
07:54AM	The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-22-19 04:01PM	Soleno Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-02-19 08:00AM	Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire +15.54%
Oct-01-19 02:22PM	We Think Soleno Therapeutics (NASDAQ:SLNO) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-24-19 08:00AM	Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire
Sep-19-19 08:00AM	Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies GlobeNewswire -5.49%
Aug-07-19 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 01:19PM	Did Changing Sentiment Drive Soleno Therapeutics's (NASDAQ:SLNO) Share Price Down By 44%? Simply Wall St.
08:00AM	Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome GlobeNewswire
Jul-15-19 09:00AM	Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jul-11-19 11:14AM	FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
Jul-01-19 08:39AM	La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks
Jun-12-19 08:00AM	Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors GlobeNewswire
May-28-19 06:07AM	Will Capnia to Surge Higher? Zacks +6.28%
May-24-19 08:49AM	What Kind Of Shareholders Own Soleno Therapeutics, Inc. (NASDAQ:SLNO)? Simply Wall St.
May-13-19 08:00AM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 04:13PM	Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
08:11AM	Small Drug Stocks Outlook: Near-Term Prospects Encouraging Zacks
Apr-29-19 08:00AM	Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors GlobeNewswire
Apr-03-19 08:00AM	Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.56%
Mar-27-19 08:46AM	Will Capnia Continue to Surge Higher? Zacks -6.42%
Mar-25-19 10:00AM	Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice Zacks
08:00AM	Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference GlobeNewswire
Mar-20-19 07:48AM	Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -10.09%
Mar-18-19 08:30AM	Soleno Therapeutics, Analyst Review and Pipeline Progress ACCESSWIRE
08:00AM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-15-19 04:05PM	Four Healthcare Stocks Picking Up Speed On Friday ACCESSWIRE +98.52%
03:00PM	Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today InvestorPlace
07:39AM	The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 05:32PM	Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome Business Wire
Mar-11-19 04:05PM	Soleno Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
Dec-19-18 04:01PM	Soleno Therapeutics Announces $16.5 Million Private Placement GlobeNewswire
Dec-12-18 06:47AM	Is Soleno Therapeutics, Inc.s (NASDAQ:SLNO) CEO Pay Justified? Simply Wall St. -8.14%
Nov-15-18 08:05AM	Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018 GlobeNewswire
08:00AM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-08-18 08:00AM	Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference GlobeNewswire -11.31%
Oct-01-18 08:00AM	Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology GlobeNewswire +5.09%
Sep-19-18 08:00AM	Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease GlobeNewswire
Sep-17-18 08:00AM	Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology GlobeNewswire
Sep-06-18 08:00AM	Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients GlobeNewswire
Sep-04-18 08:00AM	Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome GlobeNewswire
Aug-14-18 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM	Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire +8.66%
Jun-04-18 08:00AM	Soleno Therapeutics To Present Corporate Update at the BIO International Convention GlobeNewswire
May-16-18 08:00AM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-14-18 08:00AM	Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire
Apr-03-18 06:15PM	What Should You Know About Soleno Therapeutics Incs (NASDAQ:SLNO) Future? Simply Wall St.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harris William G	Director	Oct 30	Sale	1.74	2,497	4,345	66,271	Nov 03 06:55 PM
Sinclair Andrew	Director	Jun 26	Buy	1.65	3,333,330	5,499,994	10,302,602	Jul 06 04:03 PM
Abingworth LLP	10% Owner	Jun 26	Buy	1.65	3,333,330	5,499,994	10,302,602	Jul 06 04:02 PM
SCHULER JACK W	10% Owner	Jun 26	Buy	1.65	7,575,759	12,500,002	11,368,862	Jun 26 07:49 PM
SCHULER JACK W	10% Owner	Jun 10	Buy	1.97	339,083	666,807	2,071,883	Jun 12 08:32 PM
FEINBERG LARRY N	10% Owner	Jun 08	Sale	3.40	150,918	513,302	655,000	Jun 09 05:16 PM
FEINBERG LARRY N	10% Owner	Jun 05	Sale	3.34	49,325	164,578	805,918	Jun 09 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience